HLA-G inhibition was counteracted by blocking the HLA-G/ILT2 interaction showing that CD8+ILT2+ TILs may therefore constitute a subset of fully differentiated cytotoxic T cells within the tumor microenvironment, independent of the PD1+ TILs targeted by immune therapies, and specifically inhibited by HLA-G (114). The gene discussed is LILRB1; the disease is neoplasm.